About this Research Topic
Hematological malignancies encompass a diverse range of diseases, such as leukemia, lymphoma, and multiple myeloma, among others. Within the multidisciplinary treatment approach, radiation therapy holds a pivotal position in effectively managing these conditions and has shown its potential to enhance local control and overall survival rates. By precisely targeting and delivering ionizing radiation to affected areas, radiation therapy aims to destroy malignant cells, shrink tumors, and alleviate disease-related symptoms. Its integration into the therapeutic regimen for hematological malignancies underscores its significance as a valuable tool for comprehensive cancer management.
The objective of this Research Topic is to comprehensively explore and discuss the latest breakthroughs and advancements in the application of radiation therapy for the management of hematologic malignancies. This includes highlighting the incorporation of combined modality treatments, which combine radiation therapy with other therapeutic modalities, in order to maximize treatment efficacy. By bringing together cutting-edge research and clinical insights, this Research Topic aims to shed light on the evolving landscape of radiation therapy, providing valuable information regarding its optimal utilization, potential synergies with other treatment approaches, and their impact on outcomes for patients with hematologic malignancies. Insight gained from this research can contribute to refining treatment strategies and improving patient care in this crucial field.
We accept original research and review articles on the following topics:
● Advances in the use of radiation therapy in treating patients with hematologic malignancies (lymphoma, leukemia, multiple myeloma)
● Use of radiation therapy in combination with systemic therapy (chemotherapy, targeted therapies, immunotherapy)
● Use of radiation therapy in patients planned for transplant (autologous, allogenic) or CAR-T therapy.
Please note: Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
The objective of this Research Topic is to comprehensively explore and discuss the latest breakthroughs and advancements in the application of radiation therapy for the management of hematologic malignancies. This includes highlighting the incorporation of combined modality treatments, which combine radiation therapy with other therapeutic modalities, in order to maximize treatment efficacy. By bringing together cutting-edge research and clinical insights, this Research Topic aims to shed light on the evolving landscape of radiation therapy, providing valuable information regarding its optimal utilization, potential synergies with other treatment approaches, and their impact on outcomes for patients with hematologic malignancies. Insight gained from this research can contribute to refining treatment strategies and improving patient care in this crucial field.
We accept original research and review articles on the following topics:
● Advances in the use of radiation therapy in treating patients with hematologic malignancies (lymphoma, leukemia, multiple myeloma)
● Use of radiation therapy in combination with systemic therapy (chemotherapy, targeted therapies, immunotherapy)
● Use of radiation therapy in patients planned for transplant (autologous, allogenic) or CAR-T therapy.
Please note: Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Keywords: hematological malignancies, radiation therapy, leukemia, lymphoma, myeloma
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
